Edition:
United States

Merck & Co Inc (MRK)

MRK on New York Consolidated

62.53USD
20 Jan 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$62.53
Open
--
Day's High
--
Day's Low
--
Volume
277
Avg. Vol
11,144,298
52-wk High
$65.46
52-wk Low
$47.97

Select another date:

BRIEF-Ono Pharmaceutical reaches settlement with Merck and signs license agreement

* Says the co and BMS reached settlement and signed license agreement with Merck for patent infringement lawsuit against Merck, regarding anti-PD-1 antibody

Merck, Bristol-Myers agree to settle Keytruda patent suit

Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve all global patent-infringement litigation related to its cancer drug, Keytruda.

Merck, Bristol-Myers agree to settle Keytruda patent suit

Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve all global patent-infringement litigation related to its cancer drug, Keytruda.

UPDATE 1-Merck, Bristol-Myers agree to settle Keytruda patent suit

Jan 20 Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve all global patent-infringement litigation related to its cancer drug, Keytruda.

Bristol-Myers lung cancer delay slams shares, keeps Merck in lead

New YORK Bristol-Myers Squibb Co shares fell 11 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck & Co Inc's leading position in the burgeoning immuno-oncolgy field.

UPDATE 1-Bristol-Myers lung cancer delay slams shares, keeps Merck in lead

New YORK, Jan 20 Bristol-Myers Squibb Co shares fell 11 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck & Co Inc's leading position in the burgeoning immuno-oncolgy field.

US STOCKS-Wall St ends higher as Trump takes office

NEW YORK, Jan 20 U.S. stocks closed higher on Friday in a modest but broad-based advance as Donald Trump was sworn in as U.S. President, marking the first time in more than 50 years that a new commander-in-chief has been welcomed by a rising equity market on his first day in office.

Merck, Bristol-Myers agree to settle Keytruda patent suit

Jan 20 Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve a patent litigation related to its cancer drug, Keytruda.

BRIEF-Merck announces license agreement resolving Keytruda patent litigation

* Merck announces settlement and license agreement resolving Keytruda (pembrolizumab) patent litigation

Merck CEO sees Keytruda in pole position in cancer race

DAVOS, Switzerland Merck & Co's Keytruda cancer drug, which last week won a speedy review from U.S. regulators for use with chemotherapy in lung cancer, is in an increasingly strong position in a fiercely competitive market, the company's CEO said on Thursday.

Select another date: